BROOMFIELD, Colo., Sept. 17, 2015 /PRNewswire/ -- Accera, Inc., a clinical-stage biotechnology company developing therapies for central nervous system disorders, announced today its support of World Alzheimer's Day 2015 and World Alzheimer's Month. Scheduled for Sept. 21, World Alzheimer's Day provides an opportunity for Alzheimer's organizations around the world to focus their efforts on raising awareness about Alzheimer's and promote advances in research, care and prevention.
Worldwide, 47 million individuals are living with Alzheimer's disease and other dementias. That number is estimated to rise to nearly 76 million by 2030 and to almost triple to 135.5 million by 2050. It is the sixth-leading cause of death in the U.S. and is the only disease among the top 10 causes of death in America that cannot be prevented, cured or even slowed.
"Alzheimer's is a devastating disease that severely impacts both patients and their families," said Accera's president and CEO, Dr. Charles Stacey. "With no new compounds approved for the disease since 2003, patients and caregivers need an increased effort on all fronts to tackle this disease. We support the campaign's efforts to advance research, improve care for those impacted by the disease and promote brain health."
As part of its efforts, Accera is sponsoring and participating in the 2015 Denver Walk to End Alzheimer's on Saturday, Sept. 19. For information about this, visit http://act.alz.org/site/TR/Walk2015/CO-Colorado?fr_id=7365&pg=entry.
Accera, Inc. is a clinical-stage biotechnology company based in Broomfield, Colorado, developing therapies for central nervous system disorders. The company's proprietary scientific platform addresses unmet medical needs in brain health, including Alzheimer's disease. Accera is focused on the clinical development of drugs with innovative mechanisms of actions. The company's management team includes globally recognized specialists in central nervous system diseases and drug development, who together leverage the latest scientific knowledge and understanding of neurological disorders. Accera's lead product candidate is AC-1204, a ketosis-inducing compound in a Phase 3 clinical study in patients with mild to moderate Alzheimer's disease. For more information, visit www.accerapharma.com.
Follow Accera on Twitter at twitter.com/accerainc.
Accera Media Contacts:
Todd Davenport, Ph.D.
(858) 717-2310 Mobile
SOURCE Accera, Inc.